Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors

Inclusion Criteria: * No age or gender limit, though minimal weight limitations for apheresis is about 15 - 20 Kg. * Both male and female of childbearing age entering the protocol must use a medically accepted form of birth control during the study, will be required to have a negative pregnancy test for female. * patients with atypical malignant brain tumor will be eligible. * Patients must have a Karnofsky performance score of at least 60% * patients may be maintained on glucocorticoid therapy at the lowest possible dose. * Baseline hematologic studies and chemistry profiles must meet the criteria. * Tumor specimen of adequate size to yield protein concentration in sufficient quantity. * Tumor-lysate peptide must be generated in sufficient quantity to pulse the APC's for vaccination. * Patient must have no prior sensitivity to the components of the dendritic cell vaccine. * Patient must agree to consider an autopsy in the event of death in an attempt to learn more concerning the nature of this treatment and tumor biology. * Patient must be capable of signing IRB approved Research Consent and Release of medical Records form. Exclusion Criteria: * Severe pulmonary, cardiac or other systemic disease associated with an unacceptable anesthetic or operative risk. * The presence of an acute infection requiring active treatment will be criteria for delay or exclusion. * Patients with a known history of an autoimmune disorder. * Inability to give informed consent. * Pregnancy.